Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Movement disorders

Patients with spinocerebellar ataxia 38 benefit from DHA supplementation

Dietary supplementation with docosahexaenoic acid (DHA) — an omega-3 fatty acid that is essential for brain development and function — produces symptomatic improvements in patients with spinocerebellar ataxia 38 (SCA38), according to an open-label trial published in Annals of Neurology. SCA38 is caused by mutations in ELOVL5, which encodes an enzyme that is involved in DHA synthesis. Ten patients with SCA38, all of whom had already participated in a 16-week randomized controlled trial of DHA supplementation, took DHA capsules daily for a further 40 weeks. At the end of this period, the participants showed clinical improvements on two different ataxia rating scales, as well as amelioration of the cerebellar hypometabolism that is observed in individuals with SCA38.

References

  1. Manes, M. et al. Docosahexaenoic acid (DHA) is a beneficial replacement treatment for spinocerebellar ataxia 38 (SCA38). Ann. Neurol. http://dx.doi.org/10.1002/ana.25059 (2017)

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wood, H. Patients with spinocerebellar ataxia 38 benefit from DHA supplementation. Nat Rev Neurol 13, 707 (2017). https://doi.org/10.1038/nrneurol.2017.154

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2017.154

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing